AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

AbbVie Inc. (NYSE:ABBV) is a research-driven biopharmaceutical company that discovers and delivers innovative medicines and ...

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations were $2.88. Operator: Good morning, and thank you for standing by. Welcome ...

AbbVie is expected to post earnings of $2.90 per share for the current quarter, representing a year-over-year change of +3.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.4%.

Shares of AbbVie Inc. ABBV rose 1.42% to $201.47 Wednesday, on what proved to be an all-around positive trading session for ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

On April 10, 2025, AbbVie Inc. (NYSE:ABBV) stock closed at $174.20 per share with a market capitalization of $308.16 billion. ClearBridge Growth Strategy stated the following regarding AbbVie Inc ...

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

AbbVie Inc. (NYSE:ABBV) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ETCompany ParticipantsJeff Stewart - EVP and Chief Commercialization ...

AbbVie reported revenues of $15.1 billion in the last reported quarter, representing a year-over-year change of +5.6%. EPS of $2.16 for the same period compares with $2.79 a year ago.

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim ...